Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.65
0.093.52%
al cierre: -
$2.64
-0.01-0.38%
After hour: 7:40 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Esperion Therapeutics Inc ha un obiettivo di prezzo di consenso pari a $5.72, stabilito in base alle ultime valutazioni degli analisti di 10. Le ultime 3 valutazioni degli analisti sono state rilasciate da HC Wainwright & Co., HC Wainwright & Co. y Needham il septiembre 19, 2025, junio 17, 2025 y mayo 7, 2025. Con un obiettivo di prezzo medio di $12 tra le HC Wainwright & Co., HC Wainwright & Co. y Needham, c'è un implicito 354.58% upside per Esperion Therapeutics Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
HC Wainwright & Co.
Needham
Goldman Sachs
Citizens Capital Markets
JMP Securities
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Esperion Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
09/19/2025 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
06/17/2025 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
05/07/2025 | 51.53% | Needham | $5 → $4 | Maintains | Buy | |||
04/25/2025 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
04/25/2025 | 89.41% | Needham | $5 → $5 | Reiterates | Buy → Buy | |||
04/17/2025 | 13.64% | Goldman Sachs | $4 → $3 | Maintains | Neutral | |||
04/08/2025 | 89.41% | Needham | $5 → $5 | Reiterates | Buy → Buy | |||
03/20/2025 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
03/05/2025 | 51.53% | Citizens Capital Markets | $4 → $4 | Reiterates | Market Outperform → Market Outperform | |||
03/04/2025 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
02/11/2025 | 51.53% | JMP Securities | $7 → $4 | Reiterates | Market Outperform → Market Outperform | |||
02/11/2025 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
01/23/2025 | 165.17% | JMP Securities | $7 → $7 | Reiterates | Market Outperform → Market Outperform | |||
01/23/2025 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
01/10/2025 | — | HC Wainwright & Co. | — | Reiterates | Buy → Buy | |||
12/18/2024 | 51.53% | Goldman Sachs | → $4 | Reinstates | → Neutral | |||
12/17/2024 | 203.05% | Cantor Fitzgerald | → $8 | Initiates | → Overweight | |||
12/13/2024 | 127.29% | Needham | $6 → $6 | Reiterates | Buy → Buy | |||
12/13/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
12/12/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
12/03/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Maintains | Buy | |||
12/02/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
11/27/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
11/19/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
11/08/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
10/02/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
08/13/2024 | 127.29% | Needham | $8 → $6 | Maintains | Buy | |||
08/12/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
06/28/2024 | 203.05% | Needham | $8 → $8 | Reiterates | Buy → Buy | |||
06/28/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
06/20/2024 | -5.3% | B of A Securities | $2.9 → $2.5 | Downgrade | Neutral → Underperform | |||
05/22/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
05/21/2024 | 506.11% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy | |||
05/08/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
05/07/2024 | 203.05% | Needham | $8 → $8 | Reiterates | Buy → Buy | |||
04/10/2024 | 203.05% | Needham | $8 → $8 | Reiterates | Buy → Buy | |||
03/25/2024 | 506.11% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy | |||
03/25/2024 | 203.05% | Needham | $8 → $8 | Reiterates | Buy → Buy | |||
02/28/2024 | 506.11% | HC Wainwright & Co. | $22 → $16 | Maintains | Buy | |||
02/27/2024 | 203.05% | Needham | $8 → $8 | Reiterates | Buy → Buy | |||
01/03/2024 | -5.3% | B of A Securities | $4 → $2.5 | Downgrade | Buy → Neutral | |||
11/20/2023 | — | JP Morgan | — | Reinstates | → Neutral | |||
11/13/2023 | 733.4% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy | |||
11/07/2023 | 203.05% | Needham | $9 → $8 | Maintains | Buy | |||
10/02/2023 | 240.93% | Needham | → $9 | Reiterates | Buy → Buy | |||
08/28/2023 | 733.4% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy | |||
08/02/2023 | 240.93% | Needham | $10 → $9 | Maintains | Buy | |||
06/26/2023 | 733.4% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy | |||
06/15/2023 | 51.53% | B of A Securities | $1.25 → $4 | Upgrade | Underperform → Buy | |||
06/01/2023 | 733.4% | HC Wainwright & Co. | → $22 | Reiterates | → Buy | |||
05/09/2023 | 278.82% | Needham | $12 → $10 | Maintains | Buy | |||
04/18/2023 | 354.58% | Needham | → $12 | Reiterates | → Buy | |||
03/28/2023 | 354.58% | Needham | → $12 | Reiterates | → Buy | |||
03/20/2023 | 13.64% | Morgan Stanley | $9 → $3 | Maintains | Equal-Weight | |||
03/16/2023 | -43.18% | B of A Securities | $8 → $1.5 | Downgrade | Neutral → Underperform | |||
03/16/2023 | 354.58% | Needham | $16 → $12 | Maintains | Buy | |||
03/16/2023 | 733.4% | HC Wainwright & Co. | → $22 | Reiterates | → Buy | |||
03/07/2023 | 165.17% | Credit Suisse | $6.5 → $7 | Upgrade | Underperform → Neutral | |||
03/06/2023 | 468.22% | JMP Securities | → $15 | Reiterates | → Market Outperform | |||
03/06/2023 | 506.11% | Needham | $12 → $16 | Maintains | Buy | |||
03/06/2023 | 733.4% | HC Wainwright & Co. | → $22 | Reiterates | → Buy | |||
02/27/2023 | 240.93% | JP Morgan | $8 → $9 | Maintains | Neutral | |||
02/27/2023 | 203.05% | B of A Securities | → $8 | Reinstates | → Neutral | |||
02/22/2023 | 354.58% | Needham | → $12 | Reiterates | → Buy | |||
02/03/2023 | 240.93% | Morgan Stanley | → $9 | Upgrade | Underweight → Equal-Weight | |||
11/02/2022 | 240.93% | Morgan Stanley | $7 → $9 | Maintains | Underweight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Esperion Therapeutics (ESPR)?
El último precio objetivo de Esperion Therapeutics (NASDAQ:ESPR) fue comunicado por HC Wainwright & Co. el septiembre 19, 2025. La firma de analistas fijó un precio objetivo para $16.00 que espera ESPR a rise dentro de 12 meses (un posible 506.11% upside). 26 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Esperion Therapeutics (ESPR)?
La última calificación de analistas para Esperion Therapeutics (NASDAQ:ESPR) fue proporcionada por HC Wainwright & Co., y Esperion Therapeutics reiterado su buy calificación.
¿Cuándo se produjo la última revisión al alza de Esperion Therapeutics (ESPR)?
La última revisión al alza de Esperion Therapeutics Inc se produjo en junio 15, 2023, cuando B of A Securities elevó su precio objetivo a $4. B of A Securities anteriormente tenía an underperform para Esperion Therapeutics Inc.
¿Cuándo fue la última revisión a la baja de Esperion Therapeutics (ESPR)?
La última revisión a la baja de Esperion Therapeutics Inc se produjo en junio 20, 2024, cuando B of A Securities cambió su precio objetivo de $2.9 a $2.5 para Esperion Therapeutics Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Esperion Therapeutics (ESPR)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Esperion Therapeutics, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Esperion Therapeutics se registró el septiembre 19, 2025, por lo que la próxima calificación estará disponible en torno al septiembre 19, 2026.
¿Es correcta la calificación de los analistas sobre Esperion Therapeutics (ESPR)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Esperion Therapeutics (ESPR) fue un reiterado con un precio objetivo de $16.00 a $16.00. El precio actual al que cotiza Esperion Therapeutics (ESPR) es de $2.64, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.